The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial

Journal of the American Academy of Dermatology

Volumn 75, Issue 1, 2016, Pages 126-134

  Brinkhuizen, Tjinta ^a,b   Frencken, Kiki J A ^a,b   Nelemans, Patty J ^a   Hoff, Marlou L S ^a   Kelleners Smeets, Nicole W J ^a,b   Zur Hausen, Axel ^a,b   Van Der Horst, Michiel P J ^a,b   Rennspiess, Dorit ^a,b   Winnepenninckx, Véronique J L ^a,b   Van Steensel, Maurice A M ^a,b,c,d   Mosterd, Klara ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Basal cell carcinoma; Calcitriol; Diclofenac; Noninvasive; Nonsteroidal anti inflammatory drugs; Targeted therapy; Topical; Vitamin D

Indexed keywords

ANTIBIOTIC AGENT; CALCITRIOL; DICLOFENAC; KI 67 ANTIGEN; PROTEIN BCL 2; GEL; NONSTEROID ANTIINFLAMMATORY AGENT; OINTMENT; VITAMIN;

ADULT; AGED; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; APPLICATION SITE SWELLING; ARTICLE; BASAL CELL CARCINOMA; BURNING SENSATION; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EROSION; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NODULAR BASAL CELL CARCINOMA; PARESTHESIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SIDE EFFECT; SUPERFICIAL BASAL CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; VITAMIN SUPPLEMENTATION; WOUND; APOPTOSIS; CARCINOMA, BASAL CELL; CELL PROLIFERATION; CHEMISTRY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GEL; OINTMENT; PATHOLOGY; SINGLE BLIND PROCEDURE; SKIN NEOPLASMS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CALCITRIOL; CARCINOMA, BASAL CELL; CELL PROLIFERATION; DICLOFENAC; DRUG THERAPY, COMBINATION; FEMALE; GELS; HUMANS; KI-67 ANTIGEN; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OINTMENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; SINGLE-BLIND METHOD; SKIN NEOPLASMS; TREATMENT OUTCOME; VITAMINS;

EID: 84962773672     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.01.050     Document Type: Article

References (28)

1. B.A. Raasch, P.G. Buettner, and C. Garbe Basal cell carcinoma: histological classification and body-site distribution Br J Dermatol 155 2006 401 407
2. N.R. Telfer, G.B. Colver, C.A. Morton British Association of Dermatologists Guidelines for the management of basal cell carcinoma Br J Dermatol 159 2008 35 48
3. F. Bath-Hextall, M. Ozolins, S.J. Armstrong, and et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicenter, non-inferiority, randomized controlled trial Lancet Oncol 15 2014 96 105
4. A.H. Arits, K. Mosterd, B.A. Essers, and et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomized controlled trial Lancet Oncol 14 2013 647 654
5. M.H. Roozeboom, A.H. Arits, P.J. Nelemans, and N.W. Kelleners-Smeets Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials Br J Dermatol 167 2012 733 756
6. E.H. Epstein Basal cell carcinomas: attack of the hedgehog Nat Rev Cancer 8 2008 743 754
7. S.H. Yang, T. Andl, V. Grachtchouk, and et al. Pathological responses to oncogenic hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling Nat Genet 40 2008 1130 1135
8. N. Barker, and H. Clevers Mining the Wnt pathway for cancer therapeutics Nat Rev 5 2006 997 1014
9. F. Takahashi-Yanaga, and T. Sasaguri The Wnt/beta-catenin signaling pathway as a target in drug discovery J Pharmacol Sci 104 2007 293 302
10. L.F. Fecker, E. Stockfleth, I. Nindl, C. Ulrich, T. Forschner, and J. Eberle The role of apoptosis in therapy and prophylaxis of epithelial tumors by nonsteroidal anti-inflammatory drugs (NSAIDs) Br J Dermatol 156 Suppl 3 2007 25 33
11. K.K. Deeb, D.L. Trump, and C.S. Johnson Vitamin D signaling pathways in cancer: potential for anticancer therapeutics Nat Rev Cancer 7 2007 684 700
12. M.F. Bijlsma, C.A. Spek, D. Zivkovic, S. van de Water, F. Rezaee, and M.P. Peppelenbosch Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion PLoS Biol 4 2006 e232
13. J.Y. Tang, T.Z. Xiao, Y. Oda, and et al. Vitamin D3 inhibits hedgehog signaling and proliferation in murine basal cell carcinomas Cancer Prev Res (Phila) 4 2011 744 751
14. J.W. Tjiu, Y.H. Liao, S.J. Lin, and et al. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis J Invest Dermatol 126 2006 1143 1151
15. K. Muller-Decker Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence Cancer Metastasis Rev 30 2011 343 361
16. J.Y. Tang, M. Aszterbaum, M. Athar, and et al. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice Cancer Prev Res (Phila) 3 2010 25 34
17. V.D. Criscione, M.A. Weinstock, M.F. Naylor, and et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial Cancer 115 2009 2523 2530
18. J. Brechbiel, K. Miller-Moslin, and A.A. Adjei Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer Cancer Treat Rev 40 2014 750 759
19. T.J. Schnitzer, S.X. Kong, P.P. Mavros, W.L. Straus, and D.J. Watson Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database Clin Ther 23 2001 1984 1998
20. D. Vidal, X. Matias-Guiu, and A. Alomar Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis Br J Dermatol 151 2004 656 662
21. C. Ulrich, A. Johannsen, J. Rowert-Huber, M. Ulrich, W. Sterry, and E. Stockfleth Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses Eur J Dermatol 20 2010 482 488
22. D.D. Bikle, Y. Oda, and Z. Xie Vitamin D and skin cancer: a problem in gene regulation J Steroid Biochem Mol Biol 97 2005 83 91
23. W.B. Bollag, J. Ducote, and C.S. Harmon Biphasic effect of 1,25-dihydroxyvitamin D3 on primary mouse epidermal keratinocyte proliferation J Cell Physiol 163 1995 248 256
24. C. Lutzow-Holm, P. De Angelis, H. Grosvik, and O.P. Clausen 1,25-Dihydroxyvitamin D3 and the vitamin D analogue KH1060 induce hyperproliferation in normal mouse epidermis. A BrdUrd/DNA flow cytometric study Exp Dermatol 2 1993 113 120
25. M. Ulrich, and E. Stockfleth Field treatment of actinic keratoses - focus on COX-2-inhibitors Actas Dermosifiliogr 100 Suppl 2 2009 55 58
26. S.M. Swetter, J.C. Boldrick, P. Pierre, P. Wong, and B.M. Egbert Effects of biopsy-induced wound healing on residual basal cell and squamous cell carcinomas: rate of tumor regression in excisional specimens J Cutan Pathol 30 2003 139 146
27. J.J. Rippey Why classify basal cell carcinomas? Histopathology 32 1998 393 398
28. F. Wolff, A. Loipetzberger, W. Gruber, H. Esterbauer, F. Aberger, and A.M. Frischauf Imiquimod directly inhibits hedgehog signaling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation Oncogene 32 2013 5574 5581